Nature Communications (Aug 2021)
Compounds targeting OSBPL7 increase ABCA1-dependent cholesterol efflux preserving kidney function in two models of kidney disease
- Matthew B. Wright,
- Javier Varona Santos,
- Christian Kemmer,
- Cyrille Maugeais,
- Jean-Philippe Carralot,
- Stephan Roever,
- Judith Molina,
- G. Michelle Ducasa,
- Alla Mitrofanova,
- Alexis Sloan,
- Anis Ahmad,
- Christopher Pedigo,
- Mengyuan Ge,
- Jeffrey Pressly,
- Laura Barisoni,
- Armando Mendez,
- Jacopo Sgrignani,
- Andrea Cavalli,
- Sandra Merscher,
- Marco Prunotto,
- Alessia Fornoni
Affiliations
- Matthew B. Wright
- Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd
- Javier Varona Santos
- Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine
- Christian Kemmer
- Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd
- Cyrille Maugeais
- Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd
- Jean-Philippe Carralot
- Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd
- Stephan Roever
- Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd
- Judith Molina
- Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine
- G. Michelle Ducasa
- Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine
- Alla Mitrofanova
- Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine
- Alexis Sloan
- Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine
- Anis Ahmad
- Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine
- Christopher Pedigo
- Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine
- Mengyuan Ge
- Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine
- Jeffrey Pressly
- Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine
- Laura Barisoni
- Department of Pathology, University of Miami, Miller School of Medicine
- Armando Mendez
- Diabetes Research Institute, University of Miami, Miller School of Medicine
- Jacopo Sgrignani
- Institute for Research in Biomedicine, Università della Svizzera Italiana
- Andrea Cavalli
- Institute for Research in Biomedicine, Università della Svizzera Italiana
- Sandra Merscher
- Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine
- Marco Prunotto
- Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd
- Alessia Fornoni
- Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine
- DOI
- https://doi.org/10.1038/s41467-021-24890-3
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 14
Abstract
This study describes a class of small molecule compounds that promote ABCA1-dependent cholesterol efflux via a non-transcriptional mechanism, the identification of the molecular target by a chemical biology approach, and the potential of these agents for the treatment of chronic kidney diseases and potentially other diseases where lipid accumulation drives disease progression.
